MassBioDrive Spring 2024 Cohort: Browne Consulting’s Reflection

biotech background for Browne Consulting A Fractional Accounting Company's Reflection on MassBioDrive.

Dan Goddard

As a Director at Browne Consulting, Dan Goddard stands as a key point of contact for our newest clients and the life science community. Since joining Browne Consulting, Dan and the onboarding team have been a part of launching over 75 new companies.

Browne Consulting was excited to support the 2024 MassBioDrive Accelerator Program spring cohort as a curriculum expert. This eight-week program connects emerging biotech startups with industry-specific curriculum modules. The modules are led by experts, one-on-one mentorship, networking opportunities, industry connections, and more. This was our first time participating in this prestigious program as business operation and accounting experts.  

The program began with Warren Browne, Tom Linden, and me, creating a video presentation. This video will be shown to MassBioDrive cohorts as they begin the program. Next, I had the opportunity to meet with each individual company. In each meeting, I took a deeper dive to address their business operations and accounting questions. Next, program participants also met with curriculum experts in drug development, IP and legal, regulatory strategy, and fundraising. 

Afterward is a mixer, where the cohort meets the Innovation ecosystem and culminates a Demo Day where each company presents.

This year’s lineup included:


  • DoriNano aims to harness the potential of DNA origami technology to develop safe, effective, and low-cost combination nanomedicines that have precise cellular targeting with minimal effective doses of cargo for serious diseases. The company’s platform sets out to solve the past limitations of nanoparticles for delivering therapeutic cargo. This allows them to offer unique advantages, including programmable size and shape, versatile cargo conjugation, precise nanospacing/stoichiometry controls, low immunogenicity, and flexible storage condition.

Hestia Therapeutics

  • Hestia Therapeutics, lending its name from the Greek goddess of the hearth, aims to bring inflammatory cells into the tumor microenvironment to unleash anti-tumor effects from within. Currently, more than 70% of cancer patients have tumors that are shielded from the immune cells directed by checkpoint inhibitors to kill cancer cells, resulting in disease progression. Hestia is looking to provide a novel approach that will profoundly impact the lives of this segment of cancer patients. 

Koi Biotherapeutics

  • Koi Biotherapeutics is focused on solving a fundamental challenge in CAR T-cell therapy—the lack of long-term persistence of CAR T-cells post-infusion. Koi has developed a novel CAR-Enhancer protein that selectively targets CAR T-cells and promotes their development into memory cells. This enhances their activity and in vivo persistence and eliminating the need for additional engineering of CAR T-cells.

Nucyrna Therapeutics

  • Nucyrna Therapeutics aims to address the unmet medical needs in ALS and other CNS disorders through its next-gen RNA-targeting technology. Nucyrna’s oligonucleotide platform can target both Nuclear & Cytoplasmic RNA, enabling unique RNA-targeting capacities for addressing complex pathology. The company focuses on neurodegenerative diseases, and demonstrates a remarkable therapeutic index profile in CNS.

Sphinxion Therapeutics

  • Sphinxion Therapeutics leverages decades of academic research to bring forward therapeutic options targeting the sphingolipid metabolic pathway as a treatment for rare and common fibrotic diseases. Preliminary animal models in two specific diseases have been effectively treated with AAV gene therapy.


Accelerator programs such as MassBioDrive establish a strong foundation of success for the earliest stage biotech companies. They do this by aligning companies with friends, experts, and mentors to ensure their success. The next MassBioDrive accelerator program is accepting applications in late spring and we look forward to supporting their next cohort!